Fly News Breaks for June 27, 2019
Jun 27, 2019 | 05:17 EDT
Piper Jaffray analyst Matt O'Brien raised his price target for Boston Scientific to $50 from $42 following the company's analyst day and keeps an Overweight rating on the shares. The analyst believes "multiple pockets of upside" exist to Boston Scientific's long-term guidance. A "consistent stack" of new product launches in the coming years from structural heart, peripheral interventions, neuromod, endoscopy, and urology/pelvic health are still underappreciated, O'Brien tells investors in a research note. He continues to recommend the shares.
News For BSX From the Last 2 Days
There are no results for your query BSX